Peyronie Disease Questions & Answers

1. Peyronie F de la. Sur quelques obstacles qui s'opposent a l'ejaculation naturelle de la semence. Memoires de l'Academie de Chirurgie. 1743. 1:318.

2. Oberlin DT, Liu JS, Hofer MD, Milose J, Matulewicz RS, Flury SC, et al. An Analysis of Case Logs From American Urologists in the Treatment of Peyronie's Disease. Urology. 2016 Jan. 87:205-9. [QxMD MEDLINE Link].

3. Pires J, Travis M, Ellsworth P. Peyronie's Disease: Overview and Recent Treatment Advances. Urol Nurs. 2015 Jul-Aug. 35 (4):164-78. [QxMD MEDLINE Link].

4. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol. 1990 Dec. 144(6):1376-9. [QxMD MEDLINE Link].

5. Carson CC. Francois Gigot de la Peyronie (1678-1747). Invest Urol. 1981 Jul. 19(1):62-3. [QxMD MEDLINE Link].

6. Lindsay MB, Schain DM, Grambsch P, Benson RC, Beard CM, Kurland LT. The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J Urol. 1991 Oct. 146(4):1007-9. [QxMD MEDLINE Link].

7. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: results of a large survey. BJU Int. 2001 Nov. 88(7):727-30. [QxMD MEDLINE Link].

8. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol. 2004 Jun. 171(6 Pt 1):2350-3. [QxMD MEDLINE Link].

9. Herati AS, Pastuszak AW. The Genetic Basis of Peyronie Disease: A Review. Sex Med Rev. 2016 Jan. 4 (1):85-94. [QxMD MEDLINE Link].

10. Usta MF, Bivalacqua TJ, Jabren GW, Myers L, Sanabria J, Sikka SC, et al. Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease. J Urol. 2004 Feb. 171(2 Pt 1):775-9. [QxMD MEDLINE Link].

11. El-Sakka AI. Prevalence of Peyronie's disease among patients with erectile dysfunction. Eur Urol. 2006 Mar. 49(3):564-9. [QxMD MEDLINE Link].

12. Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie's disease: a case-control study. BJU Int. 2006 Mar. 97(3):570-4. [QxMD MEDLINE Link].

13. Agrawal V, Ellins E, Donald A, Minhas S, Halcox J, Ralph DJ. Systemic vascular endothelial dysfunction in Peyronie's disease. J Sex Med. 2008 Nov. 5(11):2688-93. [QxMD MEDLINE Link].

14. Casabé A, Bechara A, Cheliz G, De Bonis W, Rey H. Risk factors of Peyronie's disease. What does our clinical experience show?. J Sex Med. 2011 Feb. 8(2):518-23. [QxMD MEDLINE Link].

15. Gianazza S, Belladelli F, Leni R, Masci F, Rossi P, Gianesini G, et al. Peyronie's disease development and management in diabetic men. Andrology. 2023 Feb. 11 (2):372-378. [QxMD MEDLINE Link]. [Full Text].

16. Devine CJ Jr, Somers KD, Ladaga LE. Peyronie's disease: pathophysiology. Prog Clin Biol Res. 1991. 370:355-8. [QxMD MEDLINE Link].

17. Luangkhot R, Rutchik S, Agarwal V, Puglia K, Bhargava G, Melman A. Collagen alterations in the corpus cavernosum of men with sexual dysfunction. J Urol. 1992 Aug. 148(2 Pt 1):467-71. [QxMD MEDLINE Link].

18. Chiang PH, Chiang CP, Shen MR, Huang CH, Wang CJ, Huang IY, et al. Study of the changes in collagen of the tunica albuginea in venogenic impotence and Peyronie's disease. Eur Urol. 1992. 21(1):48-51. [QxMD MEDLINE Link].

19. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol. 1997 Oct. 158(4):1391-4. [QxMD MEDLINE Link].

20. Gonzalez-Cadavid NF, Rajfer J. Experimental models of Peyronie's disease. Implications for new therapies. J Sex Med. 2009 Feb. 6(2):303-13. [QxMD MEDLINE Link].

21. Devine CJ Jr, Jordan GH, Schlossberg SM. Surgery of the penis and urethra. Walsh PC, Retic AB, Stamey TA. Campbell's Urology. 6th ed. Philadelphia, Pa: WB Saunders; 1992. 2957-3032.

22. Erdogru T, Boz A, Koksal T, Usta MF, Yildiz A, Gungor F, et al. Penile scintigraphy with 99mTc-human immunoglobulin G: a novel method for distinguishing the unstable and stable phases of Peyronie's disease. BJU Int. 2002 Nov. 90(7):703-6. [QxMD MEDLINE Link].

23. Riversi V, Tallis V, Trovatelli S, Belba A, Volterrani L, Iacoponi F, et al. Realtime-elastosonography of the penis in patients with Peyronie's disease. Arch Ital Urol Androl. 2012 Sep. 84(3):174-7. [QxMD MEDLINE Link].

24. Shenoy-Bhangle A, Perez-Johnston R, Singh A. Penile imaging. Radiol Clin North Am. 2012 Nov. 50(6):1167-81. [QxMD MEDLINE Link].

25. Bacal V, Rumohr J, Sturm R, Lipshultz LI, Schumacher M, Grober ED. Correlation of degree of penile curvature between patient estimates and objective measures among men with Peyronie's disease. J Sex Med. 2009 Mar. 6(3):862-5. [QxMD MEDLINE Link].

26. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. 2006 Jun. 175(6):2115-8; discussion 2118. [QxMD MEDLINE Link].

27. Tanner Pharma Group Initiates Named Patient Program for XIAFLEX®. https://www.tannerpharma.com/. Available at https://www.tannerpharma.com/tanner-pharma-group-initiates-named-patient-program-xiaflex/#:~:text=March%202%2C%202020%2008%3A00%20AM%20Eastern%20Daylight%20Time&text=XIAPEX%C2%AE%2C%20also%20owned%20by,on%20safety%20or%20efficacy%20concerns.. March 2, 2020; Accessed: January 27, 2023.

28. Müller A, Mulhall JP. Peyronie's disease intervention trials: methodological challenges and issues. J Sex Med. 2009 Mar. 6(3):848-61. [QxMD MEDLINE Link].

29. Brimley SC, Yafi FA, Greenberg J, Hellstrom WJG, Tue Nguyen HM, Hatzichristodoulou G. Review of Management Options for Active-Phase Peyronie's Disease. Sex Med Rev. 2019 Apr. 7 (2):329-337. [QxMD MEDLINE Link]. [Full Text].

30. Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J Urol. 1959 Jun. 81(6):770-2. [QxMD MEDLINE Link].

31. Carson CC. Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective?. Tech Urol. 1997. 3(3):135-9. [QxMD MEDLINE Link].

32. Colletta AA, Wakefield LM, Howell FV, van Roozendaal KE, Danielpour D, Ebbs SR, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer. 1990 Sep. 62(3):405-9. [QxMD MEDLINE Link].

33. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol. 1992 Dec. 70(6):648-51. [QxMD MEDLINE Link].

34. Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. 1999 Dec. 162(6):2003-5. [QxMD MEDLINE Link].

35. Fell HB, Lawrence CE, Bagga MR, Hembry RM, Reynolds JJ. The degradation of collagen in pig synovium in vitro and the effect of colchicine. Matrix. 1989 Mar. 9(2):116-26. [QxMD MEDLINE Link].

36. Harris ED Jr, Krane SM. Effects of colchicine on collagenase in cultures of rheumatoid synovium. Arthritis Rheum. 1971 Nov-Dec. 14(6):669-84. [QxMD MEDLINE Link].

37. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease? A pilot study. Urology. 1994 Aug. 44(2):291-5. [QxMD MEDLINE Link].

38. Levine LA. Peyronie's disease: a difficult sexual dysfunction problem. West J Med. 1998 Sep. 169(3):168-9. [QxMD MEDLINE Link].

39. Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int. 2003 Apr. 91(6):522-4. [QxMD MEDLINE Link].

40. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004 Jun. 16(3):238-43. [QxMD MEDLINE Link].

41. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013 Jul. 190(1):199-207. [QxMD MEDLINE Link].

42. Ziegelmann MJ, Viers BR, McAlvany KL, Bailey GC, Savage JB, Trost LW. Restoration of Penile Function and Patient Satisfaction with Intralesional Collagenase Clostridium Histolyticum Injection for Peyronie's Disease. J Urol. 2016 Apr. 195 (4 Pt 1):1051-6. [QxMD MEDLINE Link].

43. Tsambarlis PN, Yong R, Levine LA. Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease. Int J Impot Res. 2019 Jan. 31 (1):15-19. [QxMD MEDLINE Link].

44. Wymer K, Ziegelmann M, Savage J, Kohler T, Trost L. Plaque calcification: An important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie's Disease. Urology. 2018 Jun 14. [QxMD MEDLINE Link].

45. Cocci A, Russo GI, Briganti A, Salonia A, Cacciamani G, Capece M, et al. Predictors of treatment success after collagenase Clostridium histolyticum injection for Peyronie's disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. BJU Int. 2018 May 23. [QxMD MEDLINE Link].

46. Abdel Raheem A, Johnson M, Abdel-Raheem T, Capece M, Ralph D. Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol. Sex Med Rev. 2017 Oct. 5 (4):529-535. [QxMD MEDLINE Link].

47. Capoccia E, Levine LA. Contemporary Review of Peyronie's Disease Treatment. Curr Urol Rep. 2018 May 17. 19 (7):51. [QxMD MEDLINE Link].

48. Zhang F, Xiong Y, Wang W, Wu C, Qin F, Yuan J. The efficacy and safety of intralesional injection of collagenase Clostridium histolyticum for Peyronie's disease: A meta-analysis of published prospective studies. Front Pharmacol. 2022. 13:973394. [QxMD MEDLINE Link]. [Full Text].

49. Culha M, Mutlu N, Acar O, Alici B. Patient-partner satisfaction with intracavernous medication supported with oral agents in selected cases of Peyronie's disease. A ten-month follow-up study. Int Urol Nephrol. 1999. 31(2):257-62. [QxMD MEDLINE Link].

50. Winter CC, Khanna R. Peyronie's disease. Results with dermo-jet injection of dexamethasone. J Urol. 1954. 72:400-403.

51. Williams G, Green NA. The non-surgical treatment of Peyronie's disease. Br J Urol. 1980 Oct. 52(5):392-5. [QxMD MEDLINE Link].

52. Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R. [Betamethasone versus placebo in Peyronie's disease]. Arch Ital Urol Androl. 1998 Sep. 70(4):165-8. [QxMD MEDLINE Link].

53. Lamprakopoulos A, Zorzos I, Lykourinas M. The use of betamethasone and hyaluronidase injections in the treatment of Peyronie's disease. Scand J Urol Nephrol. 2000 Dec. 34(6):355-60. [QxMD MEDLINE Link].

54. Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res. 1990 Nov. 49(5):463-6. [QxMD MEDLINE Link].

55. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol. 1994 Jun. 151(6):1522-4. [QxMD MEDLINE Link].

56. Lasser A, Vandenberg TL, Vincent MJ, Hellstrom WJ. Intraplaque verapamil injection for treatment of Peyronie's disease. J La State Med Soc. 1998 Sep. 150(9):431-4. [QxMD MEDLINE Link].

57. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology. 1998 Apr. 51(4):620-6. [QxMD MEDLINE Link].

58. Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology. 2007 May. 69(5):950-4. [QxMD MEDLINE Link].

59. Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochiai A, Naitoh Y, et al. Nicardipine vs. saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. J Sex Med. 2010 Nov. 7(11):3743-9. [QxMD MEDLINE Link].

60. Moskovic DJ, Alex B, Choi JM, Nelson CJ, Mulhall JP. Defining predictors of response to intralesional verapamil injection therapy for Peyronie's disease. BJU Int. 2011 Jul 6. [QxMD MEDLINE Link].

61. Favilla V, Russo GI, Zucchi A, Siracusa G, Privitera S, Cimino S, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017 Jul. 5 (4):771-775. [QxMD MEDLINE Link]. [Full Text].

62. Cocci A, Di Maida F, Cito G, Verrienti P, Laruccia N, Campi R, et al. Comparison of Intralesional Hyaluronic Acid vs. Verapamil for the Treatment of Acute Phase Peyronie's Disease: A Prospective, Open-Label Non-Randomized Clinical Study. World J Mens Health. 2021 Apr. 39 (2):352-357. [QxMD MEDLINE Link]. [Full Text].

63. Riedl CR, Plas E, Engelhardt P, Daha K, Pflüger H. Iontophoresis for treatment of Peyronie's disease. J Urol. 2000 Jan. 163(1):95-9. [QxMD MEDLINE Link].

64. Montorsi F, Salonia A, Guazzoni G, Barbieri L, Colombo R, Brausi M, et al. Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results. J Androl. 2000 Jan-Feb. 21(1):85-90. [QxMD MEDLINE Link].

65. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002 Dec. 168(6):2483-5. [QxMD MEDLINE Link].

66. Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol. 2003 May. 169(5):1775-8. [QxMD MEDLINE Link].

67. Di Stasi SM, Giannantoni A, Capelli G, Jannini EA, Virgili G, Storti L, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int. 2003 Jun. 91(9):825-9. [QxMD MEDLINE Link].

68. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol. 2004 Apr. 171(4):1605-8. [QxMD MEDLINE Link].

69. Wessells H. Exploring cause and effect relationships in male sexual dysfunction. J Urol. 2004 Apr. 171(4):1609-10. [QxMD MEDLINE Link].

70. Srirangam SJ, Manikandan R, Hussain J, Collins GN, O'Reilly PH. Long-term results of extracorporeal shockwave therapy for Peyronie's disease. J Endourol. 2006 Nov. 20(11):880-4. [QxMD MEDLINE Link].

71. Mirone V, Imbimbo C, Palmieri A, Fusco F. Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica. Eur Urol. 1999 Oct. 36(4):327-30. [QxMD MEDLINE Link].

72. Husain J, Lynn NN, Jones DK, Collins GN, O'Reilly PH. Extracorporeal shock wave therapy in the management of Peyronie's disease: initial experience. BJU Int. 2000 Sep. 86(4):466-8. [QxMD MEDLINE Link].

73. Hauck EW, Hauptmann A, Bschleipfer T, Schmelz HU, Altinkilic BM, Weidner W. Questionable efficacy of extracorporeal shock wave therapy for Peyronie's disease: results of a prospective approach. J Urol. 2004 Jan. 171(1):296-9. [QxMD MEDLINE Link].

74. Chung E. Peyronie's disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men. Korean J Urol. 2015 Nov. 56 (11):775-80. [QxMD MEDLINE Link].

75. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol. 2004 Feb. 171(2 Pt 1):740-5. [QxMD MEDLINE Link].

76. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol. 1991. 25(2):89-94. [QxMD MEDLINE Link].

77. Wegner HE, Andresen R, Knipsel HH, Miller K. Treatment of Peyronie's disease with local interferon-alpha 2b. Eur Urol. 1995. 28(3):236-40. [QxMD MEDLINE Link].

78. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol. 1997 Jan. 79(1):40-2. [QxMD MEDLINE Link].

79. Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl. 1999 Jul-Aug. 20(4):444-8. [QxMD MEDLINE Link].

80. Astorga R, Cantero O, Contreras D, del Rio-Martín A, Labarta-Beceiro V, Gutiérrez-Elvírez A, et al. Intralesional recombinant interferon alpha-2b in Peyronie's disease. Arch Esp Urol. 2000 Sep. 53(7):665-71. [QxMD MEDLINE Link].

81. Brake M, Loertzer H, Horsch R, Keller H. Treatment of Peyronie's disease with local interferon-alpha 2b. BJU Int. 2001 May. 87(7):654-7. [QxMD MEDLINE Link].

82. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol. 2006 Jul. 176(1):394-8. [QxMD MEDLINE Link].

83. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study. Urology. 2006 May. 67(5):1038-42. [QxMD MEDLINE Link].

84. Sokhal AK, Jain NK, Jhanwar A, Singh K, Saini DK. Prospective study to evaluate the clinical outcome of intralesional interferon-α2b in the management of Peyronie's disease. Urol Ann. 2018 Apr-Jun. 10 (2):154-158. [QxMD MEDLINE Link]. [Full Text].

85. Alkandari MH, Touma N, Carrier S. Platelet-Rich Plasma Injections for Erectile Dysfunction and Peyronie's Disease: A Systematic Review of Evidence. Sex Med Rev. 2022 Apr. 10 (2):341-352. [QxMD MEDLINE Link].

86. Alizadeh M, Karimi F, Fallah MR. Evaluation of verapamil efficacy in Peyronie's disease comparing with pentoxifylline. Glob J Health Sci. 2014 Sep 18. 6 (7 Spec No):23-30. [QxMD MEDLINE Link]. [Full Text].

87. Paulis G, Barletta D, Turchi P, Vitarelli A, Dachille G, Fabiani A, et al. Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study. Res Rep Urol. 2016. 8:1-10. [QxMD MEDLINE Link]. [Full Text].

88. Chung E, Yafi FA. Pharmacotherapy in Peyronie's disease: a state-of-the-art review on established contemporary and emerging drugs. Expert Opin Pharmacother. 2022 Jun. 23 (9):1035-1042. [QxMD MEDLINE Link].

89. Leslie S. Use of external vacuum devices in Peyronie's disease. Personal communication, Unpublished data. 2001.

90. Levine LA, Newell MM. FastSize Medical Extender for the treatment of Peyronie's disease. Expert Rev Med Devices. 2008 May. 5(3):305-10. [QxMD MEDLINE Link].

91. Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med. 2009 Feb. 6(2):558-66. [QxMD MEDLINE Link].

92. Campbell JD, Matti D, Abed H, Di Pierdominico A. Technological Advancements for Treating Erectile Dysfunction and Peyronie's Disease. Urol Clin North Am. 2022 Feb. 49 (1):175-184. [QxMD MEDLINE Link].

93. Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, Martinez-Salamanca JI, et al. Penile traction therapy with the new device 'Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study. BJU Int. 2019 Apr. 123 (4):694-702. [QxMD MEDLINE Link].

94. Ziegelmann M, Savage J, Toussi A, Alom M, Yang D, Kohler T, et al. Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial. J Urol. 2019 Sep. 202 (3):599-610. [QxMD MEDLINE Link].

95. Krishnappa P, Manfredi C, Sinha M, Arcaniolo D, Matippa P, Moncada I. Penile Modeling in Peyronie's Disease: A Systematic Review of the Literature. Sex Med Rev. 2022 Jul. 10 (3):434-450. [QxMD MEDLINE Link].

96. Incrocci L, Wijnmaalen A, Slob AK, Hop WC, Levendag PC. Low-dose radiotherapy in 179 patients with Peyronie's disease: treatment outcome and current sexual functioning. Int J Radiat Oncol Biol Phys. 2000 Jul 15. 47(5):1353-6. [QxMD MEDLINE Link].

97. Mulhall JP, Branch J, Lubrano T, Shankey TV. Radiation increases fibrogenic cytokine expression by Peyronie's disease fibroblasts. J Urol. 2003 Jul. 170(1):281-4. [QxMD MEDLINE Link].

98. Segal RL, Burnett AL. Surgical Management for Peyronie's Disease. World J Mens Health. 2013 Apr. 31(1):1-11. [QxMD MEDLINE Link].

99. Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol. 2006 Jan. 175(1):238-41. [QxMD MEDLINE Link].

100. Lue TF, El-Sakka AI. Venous patch graft for Peyronie's disease. Part I: technique. J Urol. 1998 Dec. 160(6 Pt 1):2047-9. [QxMD MEDLINE Link].

101. El-Sakka AI, Rashwan HM, Lue TF. Venous patch graft for Peyronie's disease. Part II: outcome analysis. J Urol. 1998 Dec. 160(6 Pt 1):2050-3. [QxMD MEDLINE Link].

102. Devine CJ Jr, Horton CE. Surgical treatment of Peyronie's disease with a dermal graff. J Urol. 1974 Jan. 111(1):44-9. [QxMD MEDLINE Link].

103. Treiber U, Gilbert P. Surgical treatment of Peyronie's disease. Urol Int. 1991. 47(4):240-4. [QxMD MEDLINE Link].

104. Fournier GR Jr, Lue TF, Tanagho EA. Peyronie's plaque: surgical treatment with the carbon dioxide laser and a deep dorsal vein patch graft. J Urol. 1993 May. 149(5 Pt 2):1321-5. [QxMD MEDLINE Link].

105. Ganabathi K, Dmochowski R, Zimmern PE, Leach GE. Peyronie's disease: surgical treatment based on penile rigidity. J Urol. 1995 Mar. 153(3 Pt 1):662-6. [QxMD MEDLINE Link].

106. Krishnamurti S. Penile dermal flap for defect reconstruction in Peyronie's disease: operative technique and four years' experience in 17 patients. Int J Impot Res. 1995 Dec. 7(4):195-208. [QxMD MEDLINE Link].

107. Yachia D, Erlich N. Bio-fragmentable anastomosis ring in urological surgery involving the gastrointestinal tract: early experience and a historical review of mechanical intestinal anastomosis. J Urol. 1995 May. 153(5):1426-8. [QxMD MEDLINE Link].

108. Montorsi F, Salonia A, Briganti A. Five year follow-up of plaque incision and vein grafting for Peyronie's disease. J Urol. 2004. 171:331.

109. Kadioglu A, Tefekli A, Usta M, Demirel S, Tellaloglu S. Surgical treatment of Peyronie's disease with incision and venous patch technique. Int J Impot Res. 1999 Apr. 11(2):75-81. [QxMD MEDLINE Link].

110. Arena F, Peracchia G, di Stefano C, Barbieri A, Cortellini P. Peyronie's disease--incision and dorsal vein grafting combined with contralateral plication in straightening the penis. Scand J Urol Nephrol. 1999 Jun. 33(3):181-5. [QxMD MEDLINE Link].

111. Lue TF, El-Sakka AI. Lengthening shortened penis caused by Peyronie's disease using circular venous grafting and daily stretching with a vacuum erection device. J Urol. 1999 Apr. 161(4):1141-4. [QxMD MEDLINE Link].

112. Chow AK, Sidelsky SA, Levine LA. Surgical Outcomes of Plaque Excision and Grafting and Supplemental Tunica Albuginea Plication for Treatment of Peyronie's Disease With Severe Compound Curvature. J Sex Med. 2018 Jul. 15 (7):1021-1029. [QxMD MEDLINE Link].

113. Kadioglu A, Akman T, Sanli O. Surgical treatment of Peyronie's disease: a critical analysis. Eur Urol. 2006. 49:987-97.

114. Essed E, Schroeder FH. New surgical treatment for Peyronie disease. Urology. 1985 Jun. 25(6):582-7. [QxMD MEDLINE Link].

115. Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol. 2002 May. 167(5):2066-9. [QxMD MEDLINE Link].

116. Egydio PH, Lucon AM, Arap S. A single relaxing incision to correct different types of penile curvature: surgical technique based on geometrical principles. BJU Int. 2004 Nov. 94(7):1147-57. [QxMD MEDLINE Link].

117. Kadioglu A, Sanli O, Akman T, Ersay A, Guven S, Mammadov F. Graft materials in Peyronie's disease surgery: a comprehensive review. J Sex Med. 2007 May. 4(3):581-95. [QxMD MEDLINE Link].

118. Kalsi JS, Christopher N, Ralph DJ, Minhas S. Plaque incision and fascia lata grafting in the surgical management of Peyronie's disease. BJU Int. 2006 Jul. 98(1):110-4; discussion 114-5. [QxMD MEDLINE Link].

119. Taylor FL, Levine LA. Surgical correction of Peyronie's disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J Sex Med. 2008 Sep. 5(9):2221-8; discussion 2229-30. [QxMD MEDLINE Link].

120. Wilson SK, Delk JR 2nd. A new treatment for Peyronie's disease: modeling the penis over an inflatable penile prosthesis. J Urol. 1994 Oct. 152(4):1121-3. [QxMD MEDLINE Link].

121. Hellstrom WJ, Reddy S. Application of pericardial graft in the surgical management of Peyronie's disease. J Urol. 2000 May. 163(5):1445-7. [QxMD MEDLINE Link].

122. Ralph DJ. The surgical treatment of Peyronie's disease. Eur Urol. 2006 Aug. 50(2):196-8. [QxMD MEDLINE Link].

123. Ebbehoj J, Metz P. New operation for "krummerik" (penile curvature). Urology. 1985 Jul. 26(1):76-8. [QxMD MEDLINE Link].

124. van der Horst C, Martínez Portillo FJ, Melchior D, Bross S, Alken P, Juenemann KP. Polytetrafluoroethylene versus polypropylene sutures for Essed-Schroeder tunical plication. J Urol. 2003 Aug. 170(2 Pt 1):472-5. [QxMD MEDLINE Link].

125. Van Der Horst C, Martínez Portillo FJ, Seif C, Alken P, Juenemann KP. Treatment of penile curvature with Essed-Schröder tunical plication: aspects of quality of life from the patients' perspective. BJU Int. 2004 Jan. 93(1):105-8. [QxMD MEDLINE Link].

126. Hauck EW, Bschleipfer T, Diemer T, Manning M, Schroeder-Printzen I, Weidner W. Long-term results of plaque thinning with carbide burs, small incisions and venous grafting for correcting complex penile curvature in Peyronie's disease: poor results of an "ideal" approach. J Urol. 2002 May. 167(5):2070-3. [QxMD MEDLINE Link].

127. Hatzichristou DG, Hatzimouratidis K, Apostolidis A, Tzortzis V, Bekos A, Ioannidis E. Corporoplasty using tunica albuginea free grafts for penile curvature: surgical technique and long-term results. J Urol. 2002 Mar. 167(3):1367-70. [QxMD MEDLINE Link].

128. Adeniyi AA, Goorney SR, Pryor JP, Ralph DJ. The Lue procedure: an analysis of the outcome in Peyronie's disease. BJU Int. 2002 Mar. 89(4):404-8. [QxMD MEDLINE Link].

129. Bella AJ, Beasley KA, Obied A, Brock GB. Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique. Urology. 2006 Oct. 68(4):852-7. [QxMD MEDLINE Link].

130. Sansalone S, Garaffa G, Djinovic R, Pecoraro S, Silvani M, Barbagli G, et al. Long-term results of the surgical treatment of Peyronie's disease with Egydio's technique: a European multicentre study. Asian J Androl. 2011 Jul 11. [QxMD MEDLINE Link].

131. Flores S, Choi J, Alex B, Mulhall JP. Erectile dysfunction after plaque incision and grafting: short-term assessment of incidence and predictors. J Sex Med. 2011 Jul. 8(7):2031-7. [QxMD MEDLINE Link].

132. Chung E, Clendinning E, Lessard L, Brock G. Five-year follow-up of Peyronie's graft surgery: outcomes and patient satisfaction. J Sex Med. 2011 Feb. 8(2):594-600. [QxMD MEDLINE Link].

133. Shaeer O. Trans-corporal incision of Peyronie's plaques. J Sex Med. 2011 Feb. 8(2):589-93. [QxMD MEDLINE Link].

134. Montorsi F, Salonia A, Maga T, Colombo R, Cestari A, Guazzoni G, et al. Reconfiguration of the severely fibrotic penis with a penile implant. J Urol. 2001 Nov. 166(5):1782-6. [QxMD MEDLINE Link].

135. Mulhall JP, Ahmed A, Anderson M. Penile prosthetic surgery for Peyronie's disease: defining the need for intraoperative adjuvant maneuvers. J Sex Med. 2004. 1(3):318-21. [QxMD MEDLINE Link]. [Full Text].

136. Rolle L, Ceruti C, Timpano M, Sedigh O, Destefanis P, Galletto E, et al. A new, innovative, lengthening surgical procedure for Peyronie's disease by penile prosthesis implantation with double dorsal-ventral patch graft: the "sliding technique". J Sex Med. 2012 Sep. 9 (9):2389-95. [QxMD MEDLINE Link].

137. Haney NM, Gabrielson A, Kohn TP, Hellstrom WJG. The Use of Stromal Vascular Fraction in the Treatment of Male Sexual Dysfunction: A Review of Preclinical and Clinical Studies. Sex Med Rev. 2018 Jun 27. 41:101-51. [QxMD MEDLINE Link].

138. [Guideline] Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie's Disease: AUA Guideline. J Urol. 2015 Sep. 194 (3):745-53. [QxMD MEDLINE Link]. [Full Text].

139. [Guideline] Bella AJ, Lee JC, Grober ED, Carrier S, Benard F, Brock GB. 2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature. Can Urol Assoc J. 2018 May. 12 (5):E197-E209. [QxMD MEDLINE Link]. [Full Text].

140. [Guideline] Osmonov D, Ragheb A, Ward S, Blecher G, Falcone M, Soave A, et al. ESSM Position Statement on Surgical Treatment of Peyronie's Disease. Sex Med. 2022 Feb. 10 (1):100459. [QxMD MEDLINE Link]. [Full Text].

141. Babu A, Kayes O. Recent advances in managing Peyronie's disease. F1000Res. 2020. 9:[QxMD MEDLINE Link]. [Full Text].

142. Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W, et al. Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008 Aug. 5 (8):1977-84. [QxMD MEDLINE Link].

143. Krieger JR, Rizk PJ, Kohn TP, Pastuszak A. Shockwave Therapy in the Treatment of Peyronie's Disease. Sex Med Rev. 2019 Jul. 7 (3):499-507. [QxMD MEDLINE Link].

Eli Lizza, MD Clinical Instructor, Department of Urology, Weill Cornell Medical College

Eli Lizza, MD is a member of the following medical societies: American Medical Association, American Society for Reproductive Medicine, American Urological Association, International Society for Sexual Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Edward David Kim, MD, FACS Professor of Urology, Department of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American Society for Reproductive Medicine, American Urological Association, Sexual Medicine Society of North America, Society for Male Reproduction and Urology, Society for the Study of Male Reproduction, Tennessee Medical Association

Disclosure: Nothing to disclose.

Leonard Gabriel Gomella, MD, FACS The Bernard W Godwin Professor of Prostate Cancer Chairman, Department of Urology, Associate Director of Clinical Affairs, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Leonard Gabriel Gomella, MD, FACS is a member of the following medical societies: American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Laser Medicine and Surgery, American Urological Association, Sigma Xi, The Scientific Research Honor Society, Society for Basic Urologic Research, Society of University Urologists, Society of Urologic Oncology

Disclosure: Received consulting fee from GSK for consulting; Received honoraria from Astra Zeneca for speaking and teaching; Received consulting fee from Watson Pharmaceuticals for consulting.

• Print this section
• Print the entire contents of
• Print the entire contents of article